Praxis Precision Medicines, Inc. financial data

Symbol
PRAX on Nasdaq
Industry
Pharmaceutical Preparations
Location
99 High Street, 30 Th Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.15K % +177%
Debt-to-equity 8.59 % -76.3%
Return On Equity -54.9 % +66.8%
Return On Assets -50.5 % +58.3%
Operating Margin -10.2K % -41%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.6M shares -85.5%
Common Stock, Shares, Outstanding 17.8M shares -86.2%
Entity Public Float 147M USD +42%
Common Stock, Value, Issued 14K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 18.9M shares +109%
Weighted Average Number of Shares Outstanding, Diluted 18.9M shares +109%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.61M USD -16.9%
Research and Development Expense 115M USD +18.4%
General and Administrative Expense 51.1M USD +13%
Operating Income (Loss) -164M USD -17.1%
Nonoperating Income (Expense) 13M USD +431%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43.9M USD +1.69%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -151M USD -9.77%
Earnings Per Share, Basic -5.34 USD/shares +93.8%
Earnings Per Share, Diluted -5.34 USD/shares +93.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 169M USD +66.8%
Cash, Cash Equivalents, and Short-term Investments 411M USD
Assets, Current 360M USD +248%
Property, Plant and Equipment, Net 277K USD -60.4%
Operating Lease, Right-of-Use Asset 1.37M USD -39.8%
Other Assets, Noncurrent 416K USD 0%
Assets 416M USD +290%
Accounts Payable, Current 15M USD +109%
Accrued Liabilities, Current 15.5M USD +121%
Contract with Customer, Liability, Current 1.17M USD -24.6%
Liabilities, Current 32.9M USD +95.7%
Contract with Customer, Liability, Noncurrent 293K USD -80.7%
Operating Lease, Liability, Noncurrent 436K USD -73.8%
Liabilities 33.6M USD +68.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.33M USD
Retained Earnings (Accumulated Deficit) -778M USD -24.1%
Stockholders' Equity Attributable to Parent 383M USD +341%
Liabilities and Equity 416M USD +290%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9M USD +36.5%
Net Cash Provided by (Used in) Financing Activities 183M USD +911%
Net Cash Provided by (Used in) Investing Activities -91.2M USD -368%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 17.8M shares -86.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 70.7M USD +268%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 169M USD +66.6%
Deferred Tax Assets, Valuation Allowance 181M USD +25.4%
Deferred Tax Assets, Gross 181M USD +25.2%
Operating Lease, Liability 2.5M USD -28.7%
Depreciation 112K USD +5.66%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -150M USD -9.23%
Lessee, Operating Lease, Liability, to be Paid 2.73M USD -31.8%
Property, Plant and Equipment, Gross 1.59M USD +3.24%
Operating Lease, Liability, Current 1.22M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.32M USD +1.93%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.3M USD +2.05%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 232K USD -53.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 110K USD -91.7%
Deferred Tax Assets, Operating Loss Carryforwards 74.5M USD +24.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 110K USD -91.7%
Additional Paid in Capital 1.16B USD +62.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 559K USD -24.9%
Share-based Payment Arrangement, Expense 38.5M USD +51%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%